MIVAC Development receives support from GöteborgBIO and SSP

MIVAC Development receives verification grant from GöteborgBIO and Sahlgrenska Science Park (SSP).

The grant will enable MIVAC Development to further develop and verify the therapeutic and commercial potential of a newly discovered monoclonal antibody specific for the toxic confomation of Aβ aggregates. The antibody was developed using the AβCCTM technology platform (patent pending approval). Click here to view the GöteborgBIO/SSP press release (in swedish).